700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Review Article Open Access
The reappearance of tuberculosis (TB) and resistant of Mycobacterium strains is a crucial public health concern for the treatment of TB. Some findings on the fluoroquinolone (FQs) derivatives are being developed as effective anti- TB agents. Some FQs antibiotics like ofloxacin, moxifloxacin, gatifloxacin, sparfloxacin, ciprofloxacin, levofloxacin are act as bactericidal with exceptional activity against Mtb and are presently used as second-line anti-TB drugs. The FQs exert their antibacterial effects by trapping gyrase and topoisomerase-IV enzymes on deoxyribonucleic acid (DNA) and blocking the replication and transcriptions. Unlike most other bacteriums, Mtb lacks topoisomerase-IV, but contains the genes gyrA and gyrB encoding the A and B subunits of DNA gyrase. Various new-generation FQs are under clinical trials with the aim of reducing the time periods of TB treatment while others are considered to be capable candidates for future drug development.
To read the full article Peer-reviewed Article PDF
Author(s): Mohammad Asif Asif Husain Aftab Ahmad Shah Alam Khan Mohd Rashid Karun Arora Dherya Bahl and Farah Iram
Mycobacteria, tuberculosis, drug-combinations, infectious disease